Please select the option that best describes you:
Would you offer gemcitabine/cisplatin (or other platinum-based regimens) for metastatic pancreatic cancer harboring somatic ATM mutations?
NCCN indicates only BRCA1/2 and PALB2 mutations.
Answer from: Medical Oncologist at Academic Institution
Yes, potential sensitivity to DNA-damaging agents.
Sign in or Register to read more